Testing ravulizumab for kids with IgA nephropathy
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 2 and 18 years old.
- Diagnosis of primary IgA nephropathy confirmed by kidney biopsy in the last 3 years.
- Urine protein level (UPCR) of 1.0 g/g or higher from at least 3 morning urine samples.
- Kidney function (eGFR) of 30 mL/min/1.73 m² or higher.
- Must be on a stable, maximum dose of ACE inhibitor or ARB medication for at least 3 months.
- Must have received meningococcal, Hib, and pneumococcal vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if telitacicept can safely help children aged 5–18 with IgA nephropathy or IgA vasculitis nephritis. It aims to reduce protein in the urine and protect kidney function.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
This trial tests a targeted medication called Telitacicept for children and teens with kidney inflammation caused by IgA vasculitis. It aims to reduce protein in the urine and protect kidney function.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
Hear when a new IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.